Eton Pharmaceuticals (ETON)
(Delayed Data from NSDQ)
$8.25 USD
-0.17 (-1.96%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $8.25 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Price, Consensus and EPS Surprise
ETON 8.25 -0.17(-1.96%)
Will ETON be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ETON based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ETON
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
ETON: What are Zacks experts saying now?
Zacks Private Portfolio Services
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Misses Revenue Estimates
Eton Pharma (ETON) to Report Q4 Earnings: What's in the Cards?
Moderna (MRNA) Q4 Earnings and Revenues Beat Estimates
Other News for ETON
3 Stocks Insiders Are Buying Heavily In October 2024, And Why
Opaleye Management Inc. Bolsters Portfolio with Strategic Acquisition of Eton Pharmaceuticals Shares
Domino's Pizza To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Friday
Eton Pharmaceuticals price target raised by $2 at Craig-Hallum, here's why
Wall Street Analysts Are Bullish on Top Healthcare Picks